Tetrylammonium

Tetrylammonium

SCHEMBL4331836

CCC(c1ccccc1)C(OB(O)O)(c1ccccc1)c1ccccc1.CC[N+](CC)(CC)CC

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.36
CHRM2 P08172 2/20 0.36
CHRM3 P20309 2/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 2/20 0.34
KMT2A Q03164 3/20 0.32
POLB P06746 2/20 0.32
MEN1 O00255 2/20 0.32
HKDC1 Q2TB90 1/20 0.32
CYP2D6 P10635 1/20 0.32
KCNH2 Q12809 1/20 0.32
EDNRB P24530 3/20 0.31
EDNRA P25101 3/20 0.31
CHRM4 P08173 1/20 0.31
NPC1 O15118 1/20 0.30
CHRNB2 P17787 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532851 0.93 LMNA (0.39) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
Tetramethylammonium Ion SCHEMBL2428729 0.92 LMNA (0.36) CHRM1CHRM2CHRM3CYP1A2CYP3A4
Ammonia Solution, Strong SCHEMBL8366918 0.91 LMNA (0.38) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL3623440 0.91 LMNA (0.38) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL7747171 0.91 LMNA (0.38) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
Tetrylammonium SCHEMBL4331841 0.89 CHRM2 (0.35) CHRM1CHRM2CHRM3CYP1A2CYP3A4
Trimethylammonium SCHEMBL9451107 0.89 LMNA (0.36) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
Tetrabuthylammonium SCHEMBL4807012 0.87 MEN1 (0.35) CHRM1CHRM2CHRM3CYP3A4LMNA
Tetrylammonium SCHEMBL9812209 0.86 CHRM2 (0.33) CHRM1CHRM2CHRM3CYP1A2CYP3A4
SCHEMBL8365387 0.86 SIGMAR1 (0.38) CHRM1CHRM2CHRM3CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113169268-A Piezoelectric material and composition for piezoelectric material 大阪有机化学工业株式会社 2021-07-23 CN disclosed
US-20200040117-A1 (METH)ACRYLIC RESIN AND METHOD FOR CONTROLLING STRAIN THEREOF OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) 2020-02-06 US disclosed
EP-3604358-A1 (METH)ACRYLIC RESIN AND METHOD FOR CONTROLLING STRAIN THEREOF Osaka Organic Chemical Industry Ltd. (JP) 2020-02-05 EP disclosed
WO-2020017545-A1 CURABLE RESIN COMPOSITION, (METH)ACRYLIC ELASTOMER, AND SHEET 大阪有機化学工業株式会社 2020-01-23 WO disclosed
CN-110662774-A (meth) acrylic resin and method for adjusting strain thereof 大阪有机化学工业株式会社 2020-01-07 CN disclosed
US-20090142672-A1 OPTICAL RECORDING COMPOSITION AND HOLOGRAPHIC RECORDING MEDIUM FUJIFILM CORPORATION (JP) 2009-06-04 US disclosed
US-7371466-B2 Polymerisation initiators, polymerisable compositions, and uses thereof for bonding low surface energy substrates LOCTITE (R & D) LIMITED (IE) 2008-05-13 US disclosed
US-7267886-B2 Polymerisation initiators, polymerisable compositions, and uses thereof for bonding low surface energy substrates LOCTITE (R&D) LIMITED (IE) 2007-09-11 US disclosed
US-7189463-B2 Polymerisation initiators, polymerisable compositions, and uses thereof for bonding low surface energy substrates LOCTITE (R&D) LIMITED (IE) 2007-03-13 US disclosed
US-20050154160-A1 Polymerisation initiators, polymerisable compositions, and uses thereof for bonding low surface energy substrates LOCTITE (R&D) LIMITED 2005-07-14 US disclosed
EP-1328597-B1 QUATERNARY BORON COMPOUND POLYMERISATION INITIATORS, POLYMERISABLE COMPOSITIONS AND USES THEREOF FOR BONDING LOW SURFACE ENERGY SUBSTRATES LOCTITE R & D LTD (IE) 2005-03-02 EP disclosed
US-20040068067-A1 Quratenary boron compound polymerisation initiators, polymerisable compositions, and uses thereof for bonding low surface energy substrates Henkel IP & Holding GmbH (DE) 2004-04-08 US disclosed
US-20030226472-A1 Polymerisation initiators, polymerisable compositions, and uses thereof for bonding low surface energy substrates LOCTITE (R&D) LIMITED 2003-12-11 US disclosed
WO-2003089536-A2 POLYMERISATION INITIATORS BASED ON AMMONIUM TETRAALKYL BORANES, POLYMERISABLE COMPOSITIONS, AND USES THEREOF FOR BONDING LOW SURFACE ENERGY SUBSTRATES LOCTITE (R & D) LIMITED (IE) 2003-10-30 WO disclosed
EP-1328597-A1 QUATERNARY BORON COMPOUND POLYMERISATION INITIATORS, POLYMERISABLE COMPOSITIONS AND USES THEREOF FOR BONDING LOW SURFACE ENERGY SUBSTRATES Loctite (R & D) Limited (IE) 2003-07-23 EP disclosed
WO-2002034851-A1 QUATERNARY BORON COMPOUND POLYMERISATION INITIATORS, POLYMERISABLE COMPOSITIONS, AND USES THEREOF FOR BONDING LOW SURFACE ENERGY SUBSTRATES LOCTITE (R & D) LIMITED (IE) 2002-05-02 WO disclosed
US-5854298-A Photocurable low observable aircraft materials LOCKHEED MARTIN CORPORATION (US) 1998-12-29 US disclosed
US-5153100-A Hexaarylbisimidazole and-or p-dialkylaminophenyl carbonyl compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-10-06 US disclosed
EP-0475153-A1 Borate coinitiators for photopolymerizable compositions E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-03-18 EP disclosed
EP-0434437-A2 Photohardenable or thermohardenable compositions and photosensitive materials utilising such photohardenable compositions THE MEAD CORPORATION (US) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090142672-A1 OPTICAL RECORDING COMPOSITION AND HOLOGRAPHIC RECORDING MEDIUM CRY1, CRY2, CACNA1B CHRM1 77/4885CHRM2 201/4885CHRM3 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.